2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Palliative Care, Biological Processes, Pathogenesis, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, MDS, MPN, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4426 Patient preferences for benefits, risks, and administration route of hypomethylating agents in acute myeloid leukemia

Amer M. Zeidan, MD, Sophia Zhao, PhD2, Yan Meng, PhD3, Fang Sun, MD4, Maryia Zhdanava5, Boya Lin, PhD6, Zhuo Chen7, Dominic Pilon, MA8, Harold Keer, MD, PhD9, Thomas W LeBlanc, MD, MA, MHS10
1 Yale University School of Medicine, New Haven, Connecticut, United States
2 Taiho Oncology, Princeton, New Jersey, United States
3 Analysis Group, Boston, Massachusetts, United States
4 Taiho Oncology, Princeton, New Jersey, United States
5 Analysis Group, Montreal, Quebec, Canada
6 Analysis Group, Boston, Massachusetts, United States
7 Analysis Group, Boston, Massachusetts, United States
8 Analysis Group, Boston, Massachusetts, United States
9 Taiho Oncology, Princeton, New Jersey, United States
10 Duke University School of Medicine, Durham, North Carolina, United States

Introduction

Patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy often receive intravenous (IV) or subcutaneous (SC) hypomethylating agents (HMAs). Administration of these regimens can be burdensome. Oral HMAs may reduce the treatment burden associated with administration and improve patients’ quality of life. This study aims to evaluate preferences for HMA treatments among patients with AML.

Methods

An online discrete choice experiment (DCE) survey was conducted from April to May 2026 among adults (≥65 years in the US and ≥60 years in Canada) diagnosed with AML, recruited through physician referrals. DCE treatment attributes and levels were informed by a targeted literature review and one-on-one patient interviews. Final treatment attributes included efficacy (i.e., complete remission [CR]), safety (i.e., risks of febrile neutropenia, vomiting, muscle, bone or joint pain, pneumonia), and convenience (i.e., mode of administration, frequency of administration). Patients completed a series of choice cards, each presenting two hypothetical treatment profiles with varying attribute levels, and selected their preferred option. A dominance test and a stability test were included to assess the internal choice validity. Preference weights were estimated using a mixed logit model, which were used to calculate the relative importance (RI) and willingness-to-tradeoff between treatment attributes. Predicted uptakes were modeled for treatment profiles resembling decitabine-cedazuridine (DEC-C) plus venetoclax, decitabine plus venetoclax, and azacitidine plus venetoclax. A subgroup analysis was conducted among patients who passed both validity tests and had received HMA for AML.

Results

A total of 100 eligible patients (90 from the US and 10 from Canada) completed the survey (median age, 69.6 years; 43.0% female; 70.0% White). More than half (68.0%) had been diagnosed ≤2 years ago, and 34.0% had prior HMA experience. For HMA administration, most patients reported spending 15 minutes-1 hour traveling one way (79.4%), 30 minutes-1 hour waiting before treatment administration (e.g., check-in and treatment preparation; 58.8%), 1-2 hours receiving treatment (52.9%), and 30 minutes-1 hour waiting after treatment administration (e.g., observation and discharge; 55.9%). The top concerns related to traveling for HMA administration included long commute times (35.3%), exposure to infections (32.4%), and feeling physically unwell (26.5%) during travel and while waiting at the clinic.

Among patients who passed the prespecified internal validity tests (n=83), treatments with higher efficacy, lower risks of febrile neutropenia, vomiting, and muscle, bone or joint pain, oral administration at home and less frequent administrations were preferred (P<.05), whereas risk of pneumonia did not have a statistically significant impact on treatment preference. The most important attributes, based on relative importance scores, were the risk of febrile neutropenia and CR (RI: both 33.0%), followed by frequency of administration (RI: 10.5%) and mode of administration (RI: 10.0%). Risk of vomiting (RI: 6.7%), risk of muscle, bone or joint pain (RI: 5.1%) and risk of pneumonia (RI: 1.7%) were less important. Patients were willing to accept reductions in the probability of achieving CR for better treatment convenience, including a 3.04-percentage-point reduction to switch from SC injection in a clinic to oral pill at home, and a 3.19-percentage-point reduction to switch from a 7-day to a 5-day consecutive treatment schedule. Overall, 96.2% preferred a treatment profile resembling oral DEC-C plus venetoclax if it were available to them. Subgroup analysis among patients with prior HMA experience who passed the validity tests (n=31) showed that CR (29.2%) and risk of febrile neutropenia (29.0%) remained the two most important attributes, followed by treatment mode (17.3%) and frequency (9.6%). Patients with prior HMA experience placed greater value on oral administration than the overall sample.

Conclusions

Although CR and risk of febrile neutropenia were the most important treatment attributes, patients also placed substantial value on oral administration and less frequent treatment schedules, with willingness to accept modest reductions in efficacy for decrease in treatment burden. These findings support incorporating patient preferences alongside efficacy and safety when selecting clinically appropriate treatment for AML.

Amer M. Zeidan, MD: AbbVie, Akesobio, Agios, Amgen, Astellas, BioCryst, BioThera, BeiOne, Boehringer Ingelheim, Celgene/BMS, Chiesi/Cornerstone, Daiichi-Sankyo, Dr.Reddy’s, Epizyme, Faron, Fibrogen, GSK, Glycomimetics, Genentech, Gilead, Geron, Innocare, Janssen, Jasper, Karyopharm, Kyowa Kirin, Keros, Kura, Novartis, Notable, Oncoverity, Orum, Otsuka, Pfizer, Puretech/Gallop Technology, Regeneron, Rigel, Seattle Genetics, Shattuck Labs, Schrodinger, Sumitomo, Syros, Syndax, Systimmune, Sillajen, Servier, Takeda, Treadwell, Taiho, Vincerx, and Zentalis - Consultancy (Includes expert testimony); AbbVie, Akesobio, Agios, Amgen, Astellas, BioCryst, BioThera, BeiOne, Boehringer Ingelheim, Celgene/BMS, Chiesi/Cornerstone, Daiichi-Sankyo, Dr.Reddy’s, Epizyme, Faron, Fibrogen, GSK, Glycomimetics, Genentech, Gilead, Geron, Innocare, Janssen, Jasper, Karyopharm, Kyowa Kirin, Keros, Kura, Novartis, Notable, Oncoverity, Orum, Otsuka, Pfizer, Puretech/Gallop Technology, Regeneron, Rigel, Seattle Genetics, Shattuck Labs, Schrodinger, Sumitomo, Syros, Syndax, Systimmune, Sillajen, Servier, Takeda, Treadwell, Taiho, Vincerx, and Zentalis - Consultancy (Includes expert testimony)